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Summary
Background The extensive involvement of microRNA (miRNA) in the pathophysiol-
ogy of psoriasis is well documented. However, in order for this information to
be useful in therapeutic manipulation of miRNA levels, it is essential that detailed
functional mechanisms are elucidated. miR-125b has previously been shown to
be strongly associated with psoriasis, and presents as an obvious candidate for
further investigation.
Objectives To elucidate the specific pathway and mechanism of interest in this
association.
Methods A three-step bioinformatical hypothesis-generation pipeline was per-
formed to identify genes of interest. This pipeline was based on miR-125b bind-
ing, expression in psoriatic lesions and genome-wide association study-based
evidence of involvement. The identified candidate gene was then carefully evalu-
ated using luciferase binding assays, in vitro overexpression, small interfering RNA
knock-down and downstream gene readouts.
Results Based on our bioinformatical pipeline, ubiquitin-specific peptidase 2 was
selected as a likely candidate for a mechanistic explanation for psoriasis associa-
tion. After establishing a definite connection to miR-125b, we proceeded to
show that modulation of nuclear factor kappa B-mediated inflammation is the
likely mechanism through which this miRNA gene pair functioned.
Conclusions Shedding further light on the multifactorial causes of psoriasis is essen-
tial, if the goal is to progress towards finer control of therapeutic tools in disease
management. Findings, such as the ones presented herein, are therefore necessary
in order to achieve the future of personalized medicine.
What’s already known about this topic?
• MicroRNA (MiR)-125b has previously been shown to be strongly associated with
psoriasis.
What does this study add?
• This study adds a likely molecular mechanism to the association between miR-
125b and psoriasis. Additionally, it provides a possible novel pathway for therapeu-
tic treatment.
What is the translational message?
• MiR-125b has previously been shown to be strongly associated with psoriasis.
• To benefit clinically from this knowledge it is important to understand the under-
lying mechanism.
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• USP2 was investigated as a potential mechanism mediator.
• This expanded understanding is a prerequisite if MiR-125b functionality is to be
targeted therapeutically.
Psoriasis is a common chronic inflammatory skin disease that
affects approximately 2–3% of the population. The cause of
psoriasis is still unclear and a complete cure is lacking.
Nonetheless, significant progress has been made in under-
standing the cellular immunology and biology of psoriasis.
This includes the importance of interleukin (IL)-12 and IL-23
and the T helper (Th)1 and Th17 inflammatory pathways, as
is already well established through the success of ustekinumab
in treatment of moderate-to-severe psoriasis. Likewise, it is
unsurprising that more unspecific modulation of the immune
system is beneficial in psoriasis [corticosteroids, methotrexate
and tumour necrosis factor (TNF) inhibitors]. However, a
multifactorial disease like psoriasis is likely to originate in a
complex interplay among many different effector molecules
and further studies into the specific pathophysiological path-
ways are warranted.
One particularly interesting aspect of psoriasis-specific
pathophysiological pathways is the extensive study of micro-
RNAs (miRNAs), which have been extensively discussed as
important regulators in psoriasis.1,2 Direct pharmacological
targeting of miRNAs has even been suggested.3 Undoubtedly,
the broad regulatory activity of miRNA makes it very interest-
ing from a biological point of view, but it should be noted
that it also creates the one weakness of miRNA targeting,
which is that it can be problematic to modulate pharmacologi-
cally molecules with such broad consequences. It is therefore
of interest to further elucidate the related molecular pathways
for the purpose of gaining increased pathophysiological
understanding.
In this study we set out to characterize the targets of psoria-
sis-associated miRNA, miR-125b, which have previously been
shown to be downregulated in psoriatic lesions, playing an
important role in modulating keratinocyte function.4,5 As with
all miRNAs, a number of different targets have been proposed
and characterized for each miRNA, which is not surprising
given the functionality of miRNA. Therefore, the first steps of
our study involved the search for a useful gene for further
characterization as target molecule. We required such a gene
to be (i) a direct target of a known psoriasis-associated
miRNA; (ii) to be overexpressed in psoriatic lesions; and (iii)
have evidence of causal involvement in disease formation.
The first and second requirements give a direct link to pso-
riasis and previous discoveries. The third tries to overcome the
problem that a gene upregulated in diseased tissue may be the
cause of the disease or simply a consequence of the disease.
Short of large-scale clinical drug trials and knockout animals,
it is difficult to overcome that fact. One manageable method is
the use of human genetics to investigate if natural variation in
the expression level of a gene coincides with variation in risk
of disease.6 Taken together, these methods constitute the
foundation for our selection of ubiquitin-specific protease 2
(USP2) as a potential target of interest.
Having established this, we set out to characterize the inter-
play between USP2 and miR-125b and its effects on the three
hallmarks of psoriasis: differentiation, proliferation and
inflammation. The overall aim of these experiments was to
provide new knowledge about this aspect of psoriatic patho-
genesis signalling.
Materials and methods
Selection of target gene USP2
For the miRNA target gene list, Targetscan release 62 was
used, with the default settings, using hsa-mir-125b as input in
the mammalian database, retrieving all genes with a probabil-
ity of conserved targeting score (Pct) of > 09.7
Gene expression data from psoriatic skin lesions and healthy
controls were downloaded from the Gene Expression Omnibus
entry (accession number GSE13355), and renormalized using
robust multiarray average and log2 transformation.8,9 The vali-
dation measurements shown in Figure 1b were performed on
an independent cohort from the Karolinska Institute, using
real-time polymerase chain reaction (PCR)s analysed according
to the 2DDCt methodology. Comparisons between groups were
calculated using a heteroscedastic Student’s t-test. Patients with
psoriasis had not received systemic treatments for at least
1 month, and topical therapy for at least 2 weeks before skin
biopsy. The study was approved by the Stockholm Regional
Ethics Committee, and conducted according to the principles
of the Declaration of Helsinki.
For the investigation of genetic disease association, gen-
ome-wide association data were downloaded from the dbGap
project (accession number phs000019.v1.p1) and P-values and
all odds ratios were used as reported. Genetics of gene expres-
sion data were downloaded from array express accession num-
ber E-MTAB-2232, and gene expression data were used as
provided. USP2 was measured using the ILMN_1755502
microarray probe in the 24-h LPS-stimulated dataset. Associa-
tion with genotype was calculated using an additive linear
model, in which the TT was coded as 0, the CT as 1 and the
CC genotype as 2.
Plasmid mutagenesis and 30 untranslated region
luciferase-binding assays
Firefly luciferase reporter plasmids containing the 30-untrans-
lated region (UTR) of USP2 and empty luciferase vector were
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obtained from Promega (Madison, WI, U.S.A.). The nucleo-
tides of USP2 30-UTR containing the miR-125b binding site
were cloned into psiCHECK-2 (Promega) using the restriction
sites XhoI/NotI. The 30 UTR of human USP2 was amplified by
PCR using the following primers: forward 50– GGCTCGTTG
TGCATTGCAGT – 30; reverse 50– GGCAGGACTGGAGACC – 30
To delete the seed sequence of miR-125b on the USP2
30UTR, we used a Quick-Change Site-Directed Mutagenesis kit
(Agilent Technologies, Santa Clara, CA, U.S.A.) and the fol-
lowing primers: forward 50– TTGGACCGAGTTTCTGCCCA
GGCCACC – 30; reverse 50– GGTGGCCTGGGCAGAAACTCGG
TCCAA – 30
For the reporter luciferase assay human embryonic kidney-
293 cells were co-transfected in a 12-well plate with 1 lg
psiCheck2-USP2 and/or psiCheck2-Mut and 100 nM of miR-
125b or scrambled-sequence miRNA control (Thermo Scien-
tific, Waltham, MA, U.S.A.). A Dual Luciferase Assay (Pro-
mega) was performed 24 h after transfection, according to the
manufacturer’s instructions.
Immunostaining
USP2 protein expression was analysed in frozen skin sections
using rabbit antihuman USP2 antibody (ab66556 diluted 1:
100; Abcam, Cambridge, U.K.) and antirabbit conjugated with
horseradish peroxidase (P 0448 diluted 1: 200; DAKO,
Glostrup, Denmark). Sections were mounted using Glycergel
Mounting Medium, Aqueous (DAKO). The omission of the
primary antibody in the staining procedure was used as a neg-
ative control.
Cell culture and transfection
Human adult skin epidermal keratinocytes (Cascade Biologics,
Portland, OR, U.S.A.) were cultured in EpiLife serum-free ker-
atinocyte growth medium, including human keratinocyte
growth supplement at a final Ca2+ concentration of
006 mmol L1 (Cascade Biologics). Third-passage ker-
atinocytes were used at 50–70% confluence for all experi-
ments.
Keratinocyte transfection was carried out using Lipofec-
tamine RNAiMAX (Invitrogen, Carlsbad, CA, U.S.A.), follow-
ing the manufacturer’s instructions. In total, 20 nmol L1
miRCURY™ LNA Inhibitor (Exiqon, Vedbaek, Denmark) was
used for inhibition of miR-125b. In total, 50 nmol L1 small
interfering RNA (siRNA) was used for the specific knock-
down of USP2 (Santa Cruz Biotechnology, Dallas, TX, U.S.A.).
Silencer select negative control #1 (Ambion, Austin, TX,
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Fig 1. Selection of USP2 as a candidate gene.
(a) Gene expression data extracted from gene
expression omnibus dataset GSE13355. (b)
Gene expression measured using real-time
polymerase chain reaction in an independent
cohort of samples from the Karolinska
Institute. Data were normalized to GAPDH. (c)
Immunostaining of ubiquitin-specific protease
2 (USP2) in healthy and psoriatic skin. (d)
Natural genetic variation of USP2 expression
and its effect on risk of psoriasis. Span of
USP2 expression in a sample of monocytes
from 204 individuals. This variation is
dependent on the proximal single-nucleotide
polymorphism (SNP) rs10892465, where C
alleles cause a slightly increased expression of
USP2. Expression level is given in robust
multiarray average-normalized log2
microarray units. The association calculated
according to a linear additive model is
P = 0027. (e) This SNP also has a modest
association with psoriasis, with C alleles
increasing the risk of psoriasis, here shown as
a bar graph of the per-allele odds ratio (OR)
for rs10892465, which was reported as 119
per allele (P = 0002).
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U.S.A.) was used as the negative control. Keratinocytes were
treated with TNF-a (50 ng mL1; R&D system, Minneapolis,
MN, U.S.A.) at the indicated time points. Transfection effi-
ciency for pre-miR-125b was 514  139-fold. For anti-miR-
125b experiments all measurements were below the detectable
range of 40 cycle thresholds.
Proliferation assay
5-Ethynyl-20-deoxyuridine (EdU) was added at a final concen-
tration of 10 lmol L1 to the transfected cells 2 h before har-
vesting. A Click-iT EdU Alexa Fluor 488 Flow Cytometry
Assay Kit (Invitrogen) was used according to the manufac-
turer’s instructions and analysed by flow cytometry (Beckman-
Coulter, Fullerton, CA, U.S.A.) to determine EdU-positive
cells.
Quantitative real-time polymerase chain reaction
For the quantification of USP2, involucrin, K10, IL-8, chemo-
kine (C-X-C motif) ligand (CXCL)1 and CXCL5, 20 ng cDNA
per reaction was amplified in the presence of TaqMan
Universal Master Mix (Applied Biosystems, Foster City, CA,
U.S.A.) and TaqMan Gene Expression Assay: USP2
(Hs00899199-g1), involucrin (Hs 00846307-s1), K10
(Hs01043114-g1), IL-8 (Hs00174103-m1), CXCL1
(Hs00605382-gH), CXCL5 (Hs01099660-g1) and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) [Hs02758991-g1
(Applied Biosystems); stage 1, 50 °C for 2 min, stage 2,
95 °C for 10 min and stage 3, 95 °C for 15 s, 60 °C for
1 min, repeated 45 times] in Stratagene Mx3005p (Agilent
Technologies, Santa Clara, CA, U.S.A.). Target gene expression
was normalized based on the values of the expression of
GAPDH (Applied Biosystems).
Results
Investigation of microRNA-125b targets that are
overexpressed in psoriasis
A list of target genes of miR-125b was obtained using the
TargetScan software. This TargetScan algorithm searches for
binding motifs for specific miRNAs, typically returning hun-
dreds of potential and real target genes. For miR-125, a total
of 202 genes with an aggregate binding score > 09 were
identified.
To further narrow down the list of potential candidate
genes we investigated a publicly available gene expression
microarray dataset of psoriatic skin lesions and healthy skin
biopsies. We omitted those of the 202 genes that were not
upregulated in psoriatic lesions with a minimum significance
of P < 0001 and 25-fold upregulation (corresponding to a
Bonferroni-corrected P-value of 005 for testing 202 genes).
This left 57 genes of potential interest, quite likely all having
some measure of importance in the interplay of miR-125b
and psoriasis. However, for the purpose of this study we
chose to continue with USP2. This choice was not based on
any further filtering strategies, but rather motivated by its
known function as a requirement for TNF-a-induced nuclear
factor kappa B (NFjB) signalling.10 Overexpression of USP2 in
microarray data is shown in Figure 1a. To validate the finding
of overexpression, we measured USP2 expression using real-
time PCR in an independent cohort with psoriatic lesions
(n = 25), nonlesional skin from patients with psoriasis
(n = 10) and skin from healthy volunteers (n = 22) (Fig. 1b).
In accordance with the microarray data, quantitative real-time
PCR results showed a significantly increased USP2 level in pso-
riatic skin when compared with nonlesional psoriatic skin and
healthy skin (P < 0001; Fig. 1b). In addition, we confirmed
by immunohistochemistry the presence of USP2 protein in the
corresponding frozen samples. Stronger expression of USP2
was observed in the suprabasal layer of psoriasis lesion but
not in healthy skin (Fig. 1c).
Investigation of human genetics resources for
involvement of USP in psoriasis
Using a previously published genome-wide association study
of 1446 patients with psoriasis and 1432 healthy controls, we
investigated if there were any single-nucleotide polymor-
phisms (SNPs) associated with psoriasis found near to USP2.11
The rs10892465 SNP was found to have an association with
psoriasis (P = 0002; Fig. 1d). This was significant at a false-
discovery rate of 5%, calculated over the 142 measured SNPs
found within a 500-kilobase pair (kb) range of the gene.
Additionally, this SNP was found to affect the expression level
of USP2 in monocytes. This was done in a set of lipopolysac-
charide (LPS) and interferon-stimulated monocytes for which
both gene expression and genotypes were available.12 From
the dataset of LPS-stimulated monocytes we observed that the
C allele of the SNP for risk of psoriasis caused a slight increase
in USP2 expression (P = 0027; Fig. 1c). On their own, the
confidences of these two findings are not sufficiently strong to
support USP2 as a candidate psoriasis gene, but taken together
and viewed in light of the miR-125b hypothesis, they
strengthen interest in further pursuing detailed characterization
of USP2 in the pathogenesis of psoriasis.
In vitro confirmation of the link between miR-125b and
USP2
To confirm the TargetScan observation linking miR-125b and
USP2, we generated a site-specific mutation in the miR-125b
binding site. Luciferase reporter assay revealed up to 60%
direct inhibition of USP2 by miR-125b. When the predicted
miR-125b binding site in the 30UTR of USP2 mRNA was
mutated, luciferase activity was restored (Fig. 2b).
We further performed an anti-miR knock-down experiment
and a pre-miR overexpression experiment, which showed the
expected results: that pre-miR-125b reduced USP2 expression
and that anti-miR-125b increased USP2 expression (Fig. 2c,
d). Taken together, these experiments solidified the link
© 2016 The Authors. British Journal of Dermatology
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between miR-125b and USP2, further suggesting the involve-
ment of USP2 in psoriasis.4,5 It has been shown that overex-
pression of miR-125b prohibits keratinocyte proliferation and
promotes keratinocyte differentiation.4 As a target of miR-
125b and a pivotal gene in TNF-a-induced NFjB signalling,
we therefore hypothesize that knock-down of USP2 has effects
on keratinocyte proliferation/differentiation and NFjB sig-
nalling (Fig. 2e).
Effects of USP2 and miR-125 on keratinocyte
differentiation and proliferation
A hallmark of psoriasis is the increased proliferation and
altered differentiation of keratinocytes. Accordingly, we inves-
tigated the influence of USP2 on these two aspects. Firstly, the
differentiation markers keratin 10 (K10) (Fig. 3b) and involu-
crin (Fig. 3a) were measured after transfection with siUSP2 at
the mRNA level. knock-down of USP2 significantly increased
mRNA expression of both differentiation markers. The induc-
tion of early differentiation marker K10 was also shown at the
protein level. Only a slight increase was detected in the pro-
tein expression of the late differentiation marker involucrin
(data not shown).
Secondly, the effect of USP2 knock-down on keratinocyte
proliferation was measured. We analysed the cell proliferation
rate by an EdU incorporation assay using flow cytometry and
gating on live keratinocytes (Fig. 4). This showed that siUSP2
strongly reduced keratinocyte proliferation, particularly at the
48-h time point. As reduced differentiation and increased pro-
liferation is the important cellular state in psoriasis, these two
findings are consistent with a hypothesis that USP2 modulation
could have a beneficial effect in vivo.
Exploration of USP2 and miR-125b effects on the NFjB
signalling pathway
Previously published observations that USP2 works through
the NFjB signalling pathway prompted us to investigate the
effect of miR-125b and USP2 modulation on characteristic
NFjB signalling consequences, namely regulation of IL8,
CXCL1 and CXCL5.10 The purpose of this investigation was to
gain a better understanding of the direct mechanism through
which USP2 exerted any psoriasis-related function. As
expected miR-125b knock-down increases expression of these
genes, whereas USP2 knock-down decreases expression. miR-
125 knock-down is shown in Figure 5a; IL8 expression was
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(a) (b)
Fig 3. USP2 inhibits keratinocyte differentiation. Human keratinocytes were transfected with small interfering (si)USP2 and siRNA control (con).
The cells were harvested for RNA extraction 24 h and 48 h after transfection, followed by real-time polymerase chain reaction measurement of
(a) involucrin and (b) keratin 10 (K10). The experiment was repeated three times and a representative result is shown. Each bar represents the
mean  SD. *P < 005, **P < 001. RU, relative units.
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increased 48-fold compared with antimiR-con at 24 h post-
transfection. CXCL5 and CXCL1 were upregulated threefold and
14-fold, respectively. Correspondingly, the downregulation
seen with siUSP2 treatment was 36-, 15- and 33-fold for
IL8, CXCL5 and CXCL1, respectively (Fig. 5b). Addition of 50-
fold miR-125b to keratinocytes also affected levels of IL-8 and
CXCL8, although in an upward direction (Fig. S1; see Sup-
porting Information). The USP2 knock-down experiment was
also conducted after TNF stimulation to obtain a sufficient
active level of NFjB signalling. The same suppressive effects
on NFjB signalling were shown.
Additionally, we performed a combined miR-125b and
USP2 double-knock-down experiment to confirm the interac-
tion between the effects of USP2 and miR-125b on NFjB sig-
nalling. siUSP2 alone diminished the expression of two NFjB
downstream genes to the lowest level. In combination with
miR-125b knock-down, expression of IL-8 and CXCL1 was
recovered by 21% and 43%, respectively (Fig. 5c). The
increase in NFjB signalling activity by anti-miR125b was only
observed without TNF stimulation.
Discussion
Starting with the aim of elucidating miRNA-related pathways
leading to psoriasis, we investigated potential targets of the
known psoriasis-associated miRNA, miR-125b. From a list of
57 miR-125b target genes we selected USP2, fully acknowledg-
ing that this was not the only possible candidate. However,
according to the notation that solid functional characterization
of molecular pathways is nonetheless required, we proceeded
to further elucidate the connection between miR-125b and
USP2 in psoriasis. Firstly, we firmly substantiated the relation-
ship between miRNA and the gene, using both a luciferase assay
and knock-down/overexpression assays. Secondly, we investi-
gated whether modulation of the gene had any direct effect on
the cellular events of psoriasis, namely reduced keratinocyte dif-
ferentiation and increased proliferation. Prompted by siRNA
screen findings that USP2 is a required factor for TNF-a-
induced NFjB signalling,10 we proceeded to analyse the
relationship between USP2, miR-125b and established
NFjB-induced genes. Finally, we tested whether miR-125 res-
cues the decrease in NFjB signalling otherwise caused by USP2
knock-down, which it did. Therefore, our overall conclusion is
that one effect of miR-125b is through USP2, then NFjB
signalling and, ultimately, towards a psoriasis phenotype.
A central question is how to conclude on findings for sepa-
rate target molecules for miR-125b, for example fibroblast
growth factor receptor and matrix metalloproteinase 13.4,5
Likewise, it is puzzling how both miR-125b knock-down and
overexpression can cause increased expression of IL8/CXCL1
[Fig. 5a and Fig. S1 (see Supporting Information)]. It is gen-
erally established that each miRNA has many targets.13 Thus,
the miRNA-regulated output of a pathway can depend on
interaction with different genes with different threshold levels,
and resulting complex patterns. It is therefore important to
underscore that these results only shed light on the miR-
125B–USP2 interaction, and further on the downstream effects
of USP2. We are, of course, unable to conclude on all the
effects of miR-125b. However, ultimately, understanding the
many specific arms of their regulation will lead to increased
knowledge about the pathogenesis of diseases.
An additional aspect of our interest in USP2 is the genetic
findings showing a slight, but significant, naturally occurring
variation of USP2 dependent on a single SNP (rs10892465).
Having the high-expression USP2 variant also gives individuals
a slightly higher lifetime risk of psoriasis. Expression-level
changes from natural genetic variations are much smaller than
expression-level changes seen when comparing healthy and
diseased tissue. However, a central advantage of these genetic
studies is that, unlike disease gene-expression studies, a causal-
ity link can be established, following a theory for genetic drug
candidate selection that is discussed elsewhere.6,14
The modest strength of the genetic findings is one property
of this study that could be improved. However, although larger
publicly funded genome-wide association studies have been
described, they are not accessible by other researchers.15 Like-
wise, it would be of interest to investigate if the SNP in question
has any influence on the effect of miR-125B on USP2. It is possi-
ble that miR-125b-mediated downregulation will be decreased
in patients carrying the C allele. Other limitations worth dis-
cussing are the purely in vitro set-ups for experimentation. Ide-
ally, a conditional knockout animal model would be created for
USP2. However, such undertakings were outside the scope of
our resources. However, ultimately, a main interest of all these
investigations is the identification of novel drug targets for pso-
riasis. The current setting is one of unspecific immune system
modulators as the first line of treatment, followed by more
specific targeting of drugs such as ustekinumab. In this setting,
it is beneficial to expand our knowledge towards as many other
pathways into disease as possible. This is because a broader
range of highly specific drugs is likely to go well together with
a future setting in which personalized medicine is much more
established. We hope that increased knowledge about the USP2-
dependent NFjB signalling pathway will contribute a bit
towards that goal.
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